Ebner, Nicole

[["dc.bibliographiccitation.artnumber","10"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMC neurology"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Scherbakov, Nadja"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Meisel, Andreas"],["dc.contributor.author","Haeusler, Karl Georg"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Stefan D"],["dc.contributor.author","Dirnagl, Ulrich"],["dc.contributor.author","Joebges, Michael"],["dc.contributor.author","Doehner, Wolfram"],["dc.date.accessioned","2019-07-09T11:42:18Z"],["dc.date.available","2019-07-09T11:42:18Z"],["dc.date.issued","2016"],["dc.description.abstract","BACKGROUND: Patients with stroke are at a high risk for long-term handicap and disability. In the first weeks after stroke muscle wasting is observed frequently. Early post-stroke rehabilitation programs are directed to improve functional independence and physical performance. Supplementation with essential amino acids (EAAs) might prevent muscle wasting and improve rehabilitation outcome by augmenting muscle mass and muscle strength. We aim to examine this in a double blinded, randomized placebo-controlled clinical trial. METHODS: Patients with ischemic or haemorrhagic stroke will be enrolled at begin of the early post-stroke rehabilitation in a parallel group interventional trial. Oral supplementation of EAAs or placebo will be given for 12 weeks in a double blinded manner. Physical and functional performance will be assessed by exercise testing before supplementation of EAAs as well as at discharge from the in-patient rehabilitation, at 12 weeks and 1 year afterwards. DISCUSSION: This is the first randomized double-blinded placebo-controlled clinical study aiming to assess the effect of the EAAs supplementation on muscle strength, muscle function and physical performance in stroke patients during early post-stroke rehabilitation. Supplementation of EAAs could prevent muscle mass wasting and improve functional independence after stroke. TRIAL REGISTRATION: The study is registered at the German registry for clinical trials as well as at World Health Organization (WHO; number DRKS00005577 )."],["dc.identifier.doi","10.1186/s12883-016-0531-5"],["dc.identifier.pmid","26793971"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13213"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58637"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1471-2377"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-Stroke Study)."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","611"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","620"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Scherbakov, Nadja"],["dc.contributor.author","Pietrock, Charlotte"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Springer, Jochen"],["dc.contributor.author","Schefold, Joerg C."],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Norman, Kristina"],["dc.contributor.author","Haeusler, Karl Georg"],["dc.date.accessioned","2021-06-01T10:50:54Z"],["dc.date.available","2021-06-01T10:50:54Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1002/jcsm.12400"],["dc.identifier.eissn","2190-6009"],["dc.identifier.issn","2190-5991"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16457"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/86821"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Body weight changes and incidence of cachexia after stroke"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1242"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","1249"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Garfias Macedo, Tania"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Bekfani, Tarek"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Schefold, Joerg C."],["dc.contributor.author","Lainscak, Mitja"],["dc.contributor.author","Cleland, John G. F."],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Anker, Stefan D."],["dc.date.accessioned","2021-04-14T08:24:54Z"],["dc.date.available","2021-04-14T08:24:54Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Background Skeletal muscle wasting is an extremely common feature in patients with heart failure, affecting approximately 20% of ambulatory patients with even higher values during acute decompensation. Its occurrence is associated with reduced exercise capacity, muscle strength, and quality of life. We sought to investigate if the presence of muscle wasting carries prognostic information. Methods Two hundred sixty‐eight ambulatory patients with heart failure (age 67.1 ± 10.9 years, New York Heart Association class 2.3 ± 0.6, left ventricular ejection fraction 39 ± 13.3%, and 21% female) were prospectively enrolled as part of the Studies Investigating Co‐morbidities Aggravating Heart Failure. Muscle wasting as assessed using dual‐energy X‐ray absorptiometry was present in 47 patients (17.5%). Results During a mean follow‐up of 67.2 ± 28.02 months, 95 patients (35.4%) died from any cause. After adjusting for age, New York Heart Association class, left ventricular ejection fraction, creatinine, N‐terminal pro‐B‐type natriuretic peptide, and iron deficiency, muscle wasting remained an independent predictor of death (hazard ratio 1.80, 95% confidence interval 1.01–3.19, P = 0.04). This effect was more pronounced in patients with heart failure with reduced than in heart failure with preserved ejection fraction. Conclusions Muscle wasting is an independent predictor of death in ambulatory patients with heart failure. Clinical trials are needed to identify treatment approaches to this co‐morbidity."],["dc.identifier.doi","10.1002/jcsm.12603"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17708"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81461"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Muscle wasting as an independent predictor of survival in patients with chronic heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Journal of Heart Failure"],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Arzt, Michael"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Edelmann, Frank"],["dc.contributor.author","Evertz, Ruben"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Herrmann‐Lingen, Christoph"],["dc.contributor.author","Garfias Macedo, Tania"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Noutsias, Michel"],["dc.contributor.author","Schulze, P. Christian"],["dc.contributor.author","Wachter, Rolf"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Laufs, Ulrich"],["dc.date.accessioned","2020-12-10T14:06:20Z"],["dc.date.available","2020-12-10T14:06:20Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Endpoints of large‐scale trials in chronic heart failure have mostly been defined to evaluate treatments with regard to hospitalizations and mortality. However, patients with heart failure are also affected by very severe reductions in exercise capacity and quality of life. We aimed to evaluate the effects of heart failure treatments on these endpoints using available evidence from randomized trials. Interventions with evidence for improvements in exercise capacity include physical exercise, intravenous iron supplementation in patients with iron deficiency, and – with less certainty – testosterone in highly selected patients. Erythropoiesis‐stimulating agents have been reported to improve exercise capacity in anaemic patients with heart failure. Sinus rhythm may have some advantage when compared with atrial fibrillation, particularly in patients undergoing pulmonary vein isolation. Studies assessing treatments for heart failure co‐morbidities such as sleep‐disordered breathing, diabetes mellitus, chronic kidney disease and depression have reported improvements of exercise capacity and quality of life; however, the available data are limited and not always consistent. The available evidence for positive effects of pharmacologic interventions using angiotensin‐converting enzyme inhibitors, angiotensin receptor blockers, beta‐blockers, and mineralocorticoid receptor antagonists on exercise capacity and quality of life is limited. Studies with ivabradine and with sacubitril/valsartan suggest beneficial effects at improving quality of life; however, the evidence base is limited in particular for exercise capacity. The data for heart failure with preserved ejection fraction are even less positive, only sacubitril/valsartan and spironolactone have shown some effectiveness at improving quality of life. In conclusion, the evidence for state‐of‐the‐art heart failure treatments with regard to exercise capacity and quality of life is limited and appears not robust enough to permit recommendations for heart failure. The treatment of co‐morbidities may be important for these patient‐related outcomes. Additional studies on functional capacity and quality of life in heart failure are required."],["dc.identifier.doi","10.1002/ejhf.1838"],["dc.identifier.eissn","1879-0844"],["dc.identifier.issn","1388-9842"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69857"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.publisher","John Wiley \\u0026 Sons, Ltd."],["dc.rights","This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made."],["dc.title","Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","448"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","ESC heart failure"],["dc.bibliographiccitation.lastpage","457"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Saitoh, Masakazu"],["dc.contributor.author","Dos Santos, Marcelo R."],["dc.contributor.author","Emami, Amir"],["dc.contributor.author","Ishida, Junichi"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Bekfani, Tarek"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Lainscak, Mitja"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","von Haehling, Stephan"],["dc.date.accessioned","2019-07-09T11:44:42Z"],["dc.date.available","2019-07-09T11:44:42Z"],["dc.date.issued","2017-11"],["dc.description.abstract","AIMS: We aimed to assess determinants of anorexia, that is loss of appetite in patients with heart failure (HF) and aimed to further elucidate the association between anorexia, functional capacity, and outcomes in affected patients. METHODS AND RESULTS: We assessed anorexia status among 166 patients with HF (25 female, 66 ± 12 years) who participated in the Studies Investigating Co-morbidities Aggravating HF. Anorexia was assessed by a 6-point Likert scale (ranging from 0 to 5), wherein values ≥1 indicate anorexia. Functional capacity was assessed as peak oxygen uptake (peak VO2 ), 6 min walk test, and short physical performance battery test. A total of 57 patients (34%) reported any anorexia, and these patients showed lower values of peak VO2 , 6 min walk distance, and short physical performance battery score (all P < 0.05). Using multivariate analysis adjusting for clinically important factors, only high-sensitivity C-reactive protein [odds ratio (OR) 1.24, P = 0.04], use of loop diuretics (OR 5.76, P = 0.03), and the presence of cachexia (OR 2.53, P = 0.04) remained independent predictors of anorexia. A total of 22 patients (13%) died during a mean follow-up of 22.5 ± 5.1 months. Kaplan-Meier curves for cumulative survival showed that those patients with anorexia presented higher mortality (Log-rank test P = 0.03). CONCLUSIONS: Inflammation, use of loop diuretics, and cachexia are associated with an increased likelihood of anorexia in patients with HF, and patients with anorexia showed impaired functional capacity and poor outcomes."],["dc.identifier.doi","10.1002/ehf2.12209"],["dc.identifier.pmid","28960880"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/14870"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59070"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation","info:eu-repo/grantAgreement/EC/FP7/241558/EU//SICA-HF"],["dc.relation.issn","2055-5822"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Anorexia, functional capacity, and clinical outcome in patients with chronic heart failure: results from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of the American Heart Association"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Scherbakov, Nadja"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Nave, Alexander Heinrich"],["dc.contributor.author","Jankowska, Ewa A."],["dc.contributor.author","Schefold, Jörg C."],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Fietze, Ingo"],["dc.contributor.author","Fiebach, Jochen B."],["dc.contributor.author","Haeusler, Karl Georg"],["dc.contributor.author","Doehner, Wolfram"],["dc.date.accessioned","2020-12-10T18:38:04Z"],["dc.date.available","2020-12-10T18:38:04Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1161/JAHA.117.006010"],["dc.identifier.eissn","2047-9980"],["dc.identifier.issn","2047-9980"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16973"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77178"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Sleep‐Disordered Breathing in Acute Ischemic Stroke: A Mechanistic Link to Peripheral Endothelial Dysfunction"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","60"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cachexia Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","67"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Scherbakov, Nadja"],["dc.contributor.author","Knops, Michael"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Sandek, Anja"],["dc.contributor.author","Grittner, Ulrike"],["dc.contributor.author","Dahinden, Pius"],["dc.contributor.author","Hettwer, Stefan"],["dc.contributor.author","Schefold, Joerg C."],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Anker, Stefan-D."],["dc.contributor.author","Joebges, Michael"],["dc.contributor.author","Doehner, Wolfram"],["dc.date.accessioned","2018-11-07T10:17:21Z"],["dc.date.available","2018-11-07T10:17:21Z"],["dc.date.issued","2016"],["dc.description.abstract","BackgroundC-terminal Agrin Fragment (CAF) has been proposed as a novel biomarker for sarcopenia originating from the degeneration of the neuromuscular junctions. In patients with stroke muscle wasting is a common observation that predicts functional outcome. We aimed to evaluate agrin sub-fragment CAF22 as a marker of decreased muscle mass and physical performance in the early phase after acute stroke. MethodsPatients with acute ischaemic or haemorrhagic stroke (n=123, mean age 7011y, body mass index BMI 27.04.9kg/m(2)) admitted to inpatient rehabilitation were studied in comparison to 26 healthy controls of similar age and BMI. Functional assessments were performed at begin (23 +/- 17days post stroke) and at the end of the structured rehabilitation programme (49 +/- 18days post stroke) that included physical assessment, maximum hand grip strength, Rivermead motor assessment, and Barthel index. Body composition was assessed by bioelectrical impedance analysis (BIA). Serum levels of CAF22 were measured by ELISA. ResultsCAF22 levels were elevated in stroke patients at admission (134.3 +/- 52.3pM) and showed incomplete recovery until discharge (118.2 +/- 42.7pM) compared to healthy controls (95.7 +/- 31.8pM, p<0.001). Simple regression analyses revealed an association between CAF22 levels and parameters of physical performance, hand grip strength, and phase angle, a BIA derived measure of the muscle cellular integrity. Improvement of the handgrip strength of the paretic arm during rehabilitation was independently related to the recovery of CAF22 serum levels only in those patients who showed increased lean mass during the rehabilitation. ConclusionsCAF22 serum profiles showed a dynamic elevation and recovery in the subacute phase after acute stroke. Further studies are needed to explore the potential of CAF22 as a serum marker to monitor the muscle status in patients after stroke."],["dc.identifier.doi","10.1002/jcsm.12068"],["dc.identifier.isi","000373200500007"],["dc.identifier.pmid","27066319"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13408"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41210"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Evaluation of C-terminal Agrin Fragment as a marker of muscle wasting in patients after acute stroke during early rehabilitation"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3086"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","ESC Heart Failure"],["dc.bibliographiccitation.lastpage","3094"],["dc.bibliographiccitation.volume","7"],["dc.contributor.author","Fonseca, Guilherme Wesley Peixoto da"],["dc.contributor.author","Garfias Macedo, Tania"],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Mady, Charles"],["dc.contributor.author","Takayama, Liliam"],["dc.contributor.author","Pereira, Rosa Maria Rodrigues"],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Anker, Stefan D."],["dc.contributor.author","Negrão, Carlos Eduardo"],["dc.contributor.author","Alves, Maria Janieire de Nazaré Nunes"],["dc.contributor.author","dos Santos, Marcelo Rodrigues"],["dc.contributor.author","de Souza, Francis Ribeiro"],["dc.contributor.author","von Haehling, Stephan"],["dc.date.accessioned","2021-04-14T08:23:42Z"],["dc.date.available","2021-04-14T08:23:42Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Aims Patients with Chagas disease and heart failure (HF) have a poor prognosis similar to that of patients with ischaemic or dilated cardiomyopathy. However, the impact of body composition and muscle strength changes in these aetiologies is still unknown. We aimed to evaluate these parameters across aetiologies in two distinct cohort studies [TESTOsterone‐Heart Failure trial (TESTO‐HF; Brazil) and Studies Investigating Co‐morbidities Aggravating Heart Failure (SICA‐HF; Germany)]. Methods and results A total of 64 male patients with left ventricular ejection fraction ≤40% were matched for body mass index and New York Heart Association class, including 22 patients with Chagas disease (TESTO‐HF; Brazil), and 20 patients with dilated cardiomyopathy and 22 patients with ischaemic heart disease (SICA‐HF; Germany). Lean body mass (LBM), appendicular lean mass (ALM), and fat mass were assessed by dual energy X‐ray absorptiometry. Sarcopenia was defined as ALM divided by height in metres squared \\u0026lt;7.0 kg/m2 (ALM/height2) and handgrip strength cut‐off for men according to the European Working Group on Sarcopenia in Older People. All patients performed maximal cardiopulmonary exercise testing. Forearm blood flow (FBF) was measured by venous occlusion plethysmography. Chagasic and ischaemic patients had lower total fat mass (16.3 ± 8.1 vs. 19.3 ± 8.0 vs. 27.6 ± 9.4 kg; P \\u0026lt; 0.05) and reduced peak oxygen consumption (VO2) (1.17 ± 0.36 vs. 1.15 ± 0.36 vs. 1.50 ± 0.45 L/min; P \\u0026lt; 0.05) than patients with dilated cardiomyopathy, respectively. Chagasic patients showed a trend towards decreased LBM when compared with ischaemic patients (48.3 ± 7.6 vs. 54.2 ± 6.3 kg; P = 0.09). Chagasic patients showed lower handgrip strength (27 ± 8 vs. 37 ± 11 vs. 36 ± 14 kg; P \\u0026lt; 0.05) and FBF (1.84 ± 0.54 vs. 2.75 ± 0.76 vs. 3.42 ± 1.21 mL/min/100 mL; P \\u0026lt; 0.01) than ischaemic and dilated cardiomyopathy patients, respectively. There was no statistical difference in the distribution of sarcopenia between groups (P = 0.87). In addition, FBF correlated positively with LBM (r = 0.31; P = 0.012), ALM (r = 0.25; P = 0.046), and handgrip strength (r = 0.36; P = 0.004). In a logistic regression model using peak VO2 as the dependent variable, haemoglobin (odds ratio, 1.506; 95% confidence interval, 1.043–2.177; P = 0.029) and ALM (odds ratio, 1.179; 95% confidence interval, 1.011–1.374; P = 0.035) were independent predictors for peak VO2 adjusted by age, left ventricular ejection fraction, New York Heart Association, creatinine, and FBF. Conclusions Patients with Chagas disease and HF have decreased fat mass and exhibit reduced peripheral blood flow and impaired muscle strength compared with ischaemic HF patients. In addition, patients with Chagas disease and HF show a tendency to have greater reduction in total LBM, with ALM remaining an independent predictor of reduced functional capacity in these patients. The percentage of patients affected by sarcopenia was equal between groups."],["dc.description.sponsorship","Boehringer Ingelheim and Amgen"],["dc.description.sponsorship","Innovative Medicines Initiative http://dx.doi.org/10.13039/501100010767"],["dc.description.sponsorship","German Center for Cardiovascular Research (DZHK)"],["dc.description.sponsorship","Fundação de Amparo à Pesquisa do Estado de São Paulo http://dx.doi.org/10.13039/501100001807"],["dc.description.sponsorship","Conselho Nacional de Desenvolvimento Científico e Tecnológico http://dx.doi.org/10.13039/501100003593"],["dc.description.sponsorship","Coordenação de Aperfeiçoamento de Pessoal de Nível Superior http://dx.doi.org/10.13039/501100002322"],["dc.identifier.doi","10.1002/ehf2.12936"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17699"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81017"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2055-5822"],["dc.relation.issn","2055-5822"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Muscle mass, muscle strength, and functional capacity in patients with heart failure of Chagas disease and other aetiologies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]